NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

$11.26

-0.33 (-2.85 %)

(As of 01/17/2020 04:00 PM ET)

Add

Compare

Today's Range

$11.19

Now: $11.26▼

$11.85

50-Day Range

$9.26

MA: $10.55▼

$11.91

52-Week Range

$7.43

Now: $11.26▼

$32.32

Volume401,037 shs

Average Volume555,400 shs

Market Capitalization$551.27 million

P/E RatioN/A

Dividend YieldN/A

Beta2.31

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MGNX

Previous Symbol

CUSIPN/A

CIK1125345

Webhttp://www.macrogenics.com/

Phone301-251-5172

Debt

Debt-to-Equity Ratio0.11

Current Ratio4.79

Quick Ratio4.79

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$60.12 million

Price / Sales9.17

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.75 per share

Price / Book1.96

Profitability

EPS (Most Recent Fiscal Year)($4.19)

Net Income$-171,450,000.00

Net Margins-303.08%

Return on Equity-59.67%

Return on Assets-44.82%

Miscellaneous

Employees364

Outstanding Shares48,958,000

Market Cap$551.27 million

Next Earnings Date2/25/2020 (Estimated)

OptionableOptionable

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

A Rare Upcoming Change to Bitcoin Could Yield Profits of 2,752% (Ad)

Free Report: In a few months the Bitcoin network will undergo a major change that will make it more scarce than ever before. Historically, this event has been correlated to a major price increase.

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.94) by $0.03. The biopharmaceutical company earned $18.74 million during the quarter, compared to the consensus estimate of $23.33 million. MacroGenics had a negative return on equity of 59.67% and a negative net margin of 303.08%. View MacroGenics' Earnings History.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MacroGenics.

What price target have analysts set for MGNX?

13 analysts have issued 1-year target prices for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $23.73 in the next twelve months. This suggests a possible upside of 110.8% from the stock's current price. View Analyst Price Targets for MacroGenics.

What is the consensus analysts' recommendation for MacroGenics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

What are Wall Street analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:

1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (1/9/2020)
2. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019)

Has MacroGenics been receiving favorable news coverage?

News stories about MGNX stock have trended negative on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MacroGenics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for MacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,650,000 shares, an increase of 7.0% from the December 15th total of 3,410,000 shares. Based on an average daily trading volume, of 557,900 shares, the short-interest ratio is currently 6.5 days. Currently, 8.3% of the shares of the company are sold short. View MacroGenics' Current Options Chain.

Who are some of MacroGenics' key competitors?

Some companies that are related to MacroGenics include Synthorx (THOR), Aimmune Therapeutics (AIMT), Aurinia Pharmaceuticals (AUPH), Turning Point Therapeutics (TPTX), Xencor (XNCR), Eidos Therapeutics (EIDX), Principia Biopharma (PRNB), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Ironwood Pharmaceuticals (IRWD), Heron Therapeutics (HRTX), Zymeworks (ZYME), Insmed (INSM), Pacira Biosciences (PCRX) and Tricida (TCDA).

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include Exelixis (EXEL), AbbVie (ABBV), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Incyte (INCY), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Micron Technology (MU) and Nektar Therapeutics (NKTR).

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:

Dr. Scott Koenig, CEO, Pres & Director (Age 67)
Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (2.17%) and Alpine Global Management LLC (0.03%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

Which institutional investors are buying MacroGenics stock?

MGNX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Alpine Global Management LLC. View Insider Buying and Selling for MacroGenics.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $11.26.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $551.27 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

What is MacroGenics' official website?

The official website for MacroGenics is http://www.macrogenics.com/.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.

MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		327 (Vote Outperform)
Underperform Votes:		339 (Vote Underperform)
Total Votes:		666

MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Compound Annual Growth Rate (CAGR)

Your Ultimate Investing Toolkit

Just $1.00 for your first month.